Biotech Values

[ghmm]

UTHR/Tyvaso:

I am not very good at predicting the Day-to-day movement so take this for what its worth. I thought we would go up ~400-500 million market cap on approval which would be high teens+/low 20's move.

One could argue its been inching up before. The two requirements to me are a bit curious and perhaps lacking clarity are also impacting the appreciation. The fact that they are changing the delivery system isn't bad (they were looking at others) and maybe they dumped the Aradigm system because of the safety concern. The "oropharyngeal and pulmonary toxicities" is one I hope gets more clarity in tomorrows call. I haven't seen the label or carefully read the release but I think they'll get the majority of the Ventavis users rather quickly and the vast majority of those starting an inhaled prostacylin.

I noticed some interesting developments in the lesser known trials that could give some nice upside if we get positive results too.